AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Jonsson Comprehensive Cancer Center

Status and phase: Unknown; Phase 1

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Lymphoproliferative Disorder; Lung Cancer; Lymphoma

Treatments: Drug: gemcitabine hydrochloride; Other: pharmacological study; Drug: motesanib diphosphate

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00324597

UCLA-0506055-01

CDR0000481095

Details and patient eligibility

About

RATIONALE: AMG 706 may stop the growth of cancer cells by blocking blood flow to the cancer or by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving AMG 706 together with gemcitabine may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of AMG 706 when given together with gemcitabine in treating patients with advanced solid tumors or lymphoma.

Full description

OBJECTIVES:

Primary

• Determine the maximum tolerated dose and safety of AMG 706 when given in combination with gemcitabine hydrochloride in patients with advanced solid tumors or lymphoma.

Secondary

• Determine the pharmacokinetic profiles of this regimen in these patients.

OUTLINE: This is a multicenter, open-label, dose-escalation study of AMG 706.

Patients receive oral AMG 706 once daily on days 2-56 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 of course 1. For all subsequent courses, patients receive oral AMG 706 on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of AMG 706 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity.

During the first course of study treatment, patients undergo blood collection periodically for pharmacokinetic analysis.

After completion of study treatment, patients are followed periodically for up to 5 years.

PROJECTED ACCRUAL: Approximately 18 patients will be accrued for this study.

Enrollment: 18 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed advanced solid tumors or lymphoma
• Must have measurable disease outside a previously irradiated field OR regrowth of tumor within a previously irradiated field
• Must be a candidate for gemcitabine hydrochloride treatment, in the opinion of the investigator
• No untreated or symptomatic brain metastases
• No tumors with direct bowel invasion
• No other hematological malignancies
• No non-small cell lung cancer of squamous cell histology or large central tumor (lesions ≥ 3 cm and located adjacent to or within the hilum or mediastinum)

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Not pregnant
• No nursing during and for 6 months after completion of study treatment
• Fertile patients must use effective contraception during and for 6 months after completion of study treatment
• Negative pregnancy test
• Able to swallow oral medication
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 g/dL
• Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min
• Albumin-adjusted calcium ≥ 8 mg/dL
• Urine protein < 30 mg/dL by urinalysis or < 1+ by dipstick OR < 500 mg by 24-hour urine collection
• AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastasis or primary hepatic neoplasm)
• Bilirubin ≤ 2 times ULN
• PT ≤ 2.0
• INR or PTT ≤ 1.5 times ULN
• Systolic blood pressure (BP) ≤ 145 mm Hg and diastolic BP ≤ 85 mm Hg (stable antihypertensive medication allowed)
• No myocardial infraction within the past year
• No arterial thrombosis or deep vein thrombosis within the past year
• No unstable angina
• No congestive heart failure
• No New York Heart Association class III-IV cardiac disease
• No other unstable or uncontrolled disease or condition relating to or impacting cardiac function
• No HIV positivity
• No other condition that would preclude study participation, compliance, or follow-up assessments

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior enrollment into this study

• At least 1 month since prior investigational device or drug trial

• At least 1 month since prior major surgical procedure

• At least 3 weeks since prior systemic chemotherapy

• At least 2 weeks since prior radiotherapy

• At least 2 weeks since prior rifampin or phenobarbital

• At least 1 week since prior treatment with any of the following:

  • Ketoconazole
  • Itraconazole
  • Clarithromycin
  • Erythromycin
  • Cyclosporine or tacrolimus
  • Nefazodone
  • Herbal medications containing Hypericum perforatum (St. John's wort)

• At least 1 week since prior and no concurrent warfarin

  • Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin [≤ 2 mg/day] or low molecular weight heparin) for venous or arterial access devices allowed

• No prior or concurrent kinase insert domain-receptor inhibitors

• No concurrent chemotherapy, radiotherapy, hormone-directed cancer therapy, or tumor-directed antibody therapy

  • Gonadotropin releasing-hormone agonist therapy allowed

• No concurrent interferon

• No concurrent grapefruit juice or whole grapefruit

• No other concurrent standard or investigational drugs or antitumor treatment, including c-kit, platelet-derived growth factor, vascular endothelial growth factor, or epidermal growth factor inhibitors

• No elective surgery during or for 2 weeks after completion of the last dose of AMG 706